Shares of Inari Medical Inc. (Nasdaq: NARI), an Irvine medical device company that treats patients suffering from venous diseases, rose as much as 10% after reporting fourth-quarter preliminary results that topped analysts’ consensus expectations.
Revenue is expected to be between $82.8 million and $83.3 million for the fourth quarter, up 71% at the midpoint from the same period a year ago. The consensus analyst estimate was $73.2 million.
In after-market trading, shares climbed 10% to $93.50. The company had a $4.3 billion market cap at today’s closing. Â
“Despite the challenging operating environment, we are pleased with our continued crisp execution, not only commercially but across all of our growth drivers,” Inari CEO Bill Hoffman said in a statement.
The company said doctors treated 7,700 patients, an increase of 1,000 procedures, or 15%, from 6,700 procedures completed in the third quarter.
